# Imaging for molecular and pathological subtyping of hepatocellular carcinoma—a critical appraisal and future directions

**Authors:** Xinyuan Jia, Hanyu Jiang, Zheng Ye, Hong Wei, Jie Chen, Yali Qu, Claude B. Sirlin, Bin Song, Yanshu Wang

PMC · DOI: 10.1007/s00330-025-12075-1 · European Radiology · 2025-10-30

## TL;DR

This paper reviews how imaging techniques like CT and MRI can help identify different types of liver cancer and guide personalized treatment.

## Contribution

The paper proposes integrating imaging, clinical, and molecular data to improve HCC subtype classification and treatment decisions.

## Key findings

- Imaging features correlate with HCC molecular and pathological subtypes but lack one-to-one reliability.
- Combining imaging with clinical and molecular data may enhance prognostication and treatment strategies.
- Non-invasive imaging could reduce reliance on invasive histopathological analysis for HCC subtyping.

## Abstract

Hepatocellular carcinoma (HCC) is characterized by distinct molecular and pathological subtypes, each with unique prognostic implications. This review aims to synthesize the imaging features associated with these HCC subtypes and discuss their potential to guide therapeutic decision-making.

We searched PubMed and Embase for articles published from September 2004 to December 2024. The search strategy combined terms for imaging modalities (“CT,” “MRI”), the primary disease (“hepatocellular carcinoma”), and various molecular and pathological subtypes (e.g., “macrotrabecular-massive,” “steatohepatitic,” “CK19,” and “CTNNB1”).

HCC is a biologically heterogeneous malignancy with varied prognosis and sensitivity to treatment. Assessment of its molecular and pathological subtypes relies on invasive histopathological examination, which is subject to sampling errors and often unavailable prior to treatment selection. A growing body of evidence suggests that radiologic features aid in the non-invasive classification of HCC subtypes, thereby informing individualized therapy. Given the substantial overlap between molecular, pathological, and imaging features, this review hypothesize that a comprehensive phenotyping system integrating all these information could significantly enhance personalized prognostication and treatment strategies.

Radiologic imaging features not only provide valuable information for identifying molecular and pathological subtypes of HCC but also serve as practical tools to guide individualized therapeutic decision-making.

Question
Can CT and MRI reliably infer the molecular classification and pathological subtypes that drive prognosis in HCC?

Findings
Several imaging features have been found to reflect underlying molecular and pathological subtypes, but they do not demonstrate a one-to-one correlation.

Clinical relevance
An integrated classification system incorporating clinical, imaging, pathological, and molecular data may help mitigate the limitations of histologic and molecular analyses and facilitate individualized prognostication.

## Linked entities

- **Genes:** KRT19 (keratin 19) [NCBI Gene 3880], CTNNB1 (catenin beta 1) [NCBI Gene 1499]
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, KRT19 (keratin 19) [NCBI Gene 3880] {aka CK19, K19, K1CS}
- **Diseases:** malignancy (MESH:D009369), HCC (MESH:D006528)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13035535/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13035535/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC13035535/full.md

---
Source: https://tomesphere.com/paper/PMC13035535